Sorin reports first implant of Mitroflow Valsalva Conduit in Europe

10 November 2013 (Last Updated November 10th, 2013 18:30)

Sorin Group has announced the first European implant of Mitroflow Valsalva Conduit at Sant'Orsola-Malpighi Hospital, Bologna, Italy.

Valsalva

Sorin Group has announced the first European implant of Mitroflow Valsalva Conduit at Sant'Orsola-Malpighi Hospital, Bologna, Italy.

It is designed to be used in combination with Sorin's Mitroflow aortic pericardial heart valve.

The Mitroflow Valsalva Conduit is reportedly the only aortic root surgery system currently available in the market with bovine pericardium valve.

In addition to Mitroflow's excellent haemodynamic performance and proven long-term durability, the system offers cardiac surgeons with a solution for replacing simultaneously the ascending aorta and the diseased aortic valve in a single procedure.

The Mitroflow graft, which is impregnated with absorbable bovine cross-linked gelatine for eliminating the need for preclotting, also replicates the native sinus, preserving the patient's physiological haemodynamics and obviating the need for lifelong anticoagulation treatment.

Mitroflow Valsalva Conduit allows for safer device manipulation during assembly and implantation, thus limiting cardiac surgery time.

The implant was performed by Professor Roberto di Bartolomeo, chief of the cardiac surgery department at Sant'Orsola-Malpighi Hospital, Bologna, Italy.

Professor Roberto di Bartolomeo said with Mitroflow Valsalva Conduit, Sorin Group offers a very intuitive approach to aortic root surgery procedures.

"The introduction of Sorin's Mitroflow Valsalva Conduit in Europe represents a key milestone in Sorin's strategic innovation plan."

"I expect Sorin's innovative approach will contribute to make aortic root system reconstructions more accurate and procedural times shorter, thus allowing surgeons to set even higher standards of care," di Bartolomeo said.

Introduced in the US at the end of 2012 following the US Food and Drug Administration (FDA) approval, the Mitroflow Valsalva Conduit has recently received CE mark and is now commercially available in Europe.

Sorin Group cardiac surgery business unit president Michel Darnaud said the company is committed to providing clinicians around the world with innovative and integrated solutions targeted to improving patient care and health economic outcomes.

"We are very pleased to extend Mitroflow Valsalva Conduit's commercial availability in Europe and thus allow a larger patient population to benefit from this unique reconstructive technology," Darnaud said.

"The introduction of Sorin's Mitroflow Valsalva Conduit in Europe represents a key milestone in Sorin's strategic innovation plan."

According to GlobalData estimates, the tissue heart valves market in Europe was valued at $378m in 2012 and is expected to grow at a CAGR of 5.1% to reach $537m by 2019.


Image: The new heart device for simultaneous implantation of an aortic tissue valve and ascending aorta. Photo: courtesy of Sorin Group.